Adaptive Biotechnologies (ADPT) Change in Accured Expenses (2018 - 2026)

Adaptive Biotechnologies has reported Change in Accured Expenses for 9 years, with the latest figure at -$7.5 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 22.28% year-over-year to -$7.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 155.77% YoY) and the FY2025 annual result came in at $665000.0, down 0.89% from the prior year.
• Change in Accured Expenses declined to -$7.5 million in Q1 2026 per ADPT's latest filing, from $1.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $10.5 million in Q4 2022 and troughed at -$15.9 million in Q1 2023.
• A 5-year average of -$263058.8 and a median of $407000.0 in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses plunged 150.71% in 2023, then surged 10093.22% in 2025.
• Over 5 years, Change in Accured Expenses stood at $10.5 million in 2022, then tumbled by 49.3% to $5.3 million in 2023, then declined by 20.13% to $4.3 million in 2024, then slumped by 72.68% to $1.2 million in 2025, then sank by 744.81% to -$7.5 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$7.5 million, $1.2 million, and $5.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.